Study of Novel Types of Familial Diabetes Insipidus - Full Text View

Purpose

OBJECTIVES:

I. Define the phenotype and genotype of previously unrecognized types of familial diabetes insipidus (FDI) in kindreds with atypical or novel forms of FDI.

Condition	Intervention
Diabetes Insipidus	Drug: desmopressin

MedlinePlus related topics:

Diabetes Diabetes Insipidus

Drug Information available for:

Desmopressin Desmopressin acetate

U.S. FDA Resources

Study Type:	Observational
Study Design:	Screening

Further study details as provided by Office of Rare Diseases (ORD):

Estimated Enrollment:	5
Study Start Date:	December 1995

Detailed Description:

PROTOCOL OUTLINE: Participants undergo a series of tests to determine the presence, absence, cause, natural history, clinical status, and mode of inheritance of their type of diabetes insipidus (DI). The studies include measurements of basal fluid intake and urine output, plasma vasopressin during standard fluid deprivation or waterload/saline infusion tests, and changes in water balance during a therapeutic trial of DDAVP. If clinically indicated, echocardiograms and assays of plasma catecholes and renin are also completed.

Linkage analysis is performed for all participants; kindreds with the Marfan-like syndrome are also studied for the fibrillin-1 genotype.

Participants determined to have DI are treated with desmopressin for 2 days.

Eligibility

Ages Eligible for Study:	6 Months to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Familial diabetes insipidus (DI) in atypical or novel form, e.g.: Dipsogenic DI Neurohypophyseal DI
Affected and unaffected members of kindreds eligible

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00004364

Sponsors and Collaborators

National Center for Research Resources (NCRR)

Northwestern University

Investigators


Study Chair:	Gary L. Robertson	Northwestern University

More Information

Study ID Numbers:	199/11939, NU-570
First Received:	October 18, 1999
Last Updated:	February 21, 2006
ClinicalTrials.gov Identifier:	NCT00004364
Health Authority:	United States: Federal Government

Keywords provided by Office of Rare Diseases (ORD):

diabetes insipidus

endocrine disorders

rare disease

Study placed in the following topic categories:

Metabolic Diseases

Pituitary Diseases

Diabetes Mellitus

Rare Diseases

Endocrine System Diseases

Arginine Vasopressin

Urologic Diseases

Diabetes Insipidus

Deamino Arginine Vasopressin

Vasopressins

Kidney Diseases

Endocrinopathy

Glucose Metabolism Disorders

Metabolic disorder

Additional relevant MeSH terms:

Coagulants

Natriuretic Agents

Therapeutic Uses

Hematologic Agents

Physiological Effects of Drugs

Cardiovascular Agents

Antidiuretic Agents

Hemostatics

Pharmacologic Actions

ClinicalTrials.gov processed this record on November 20, 2008

Sponsors and Collaborators:	National Center for Research Resources (NCRR) Northwestern University
Information provided by:	Office of Rare Diseases (ORD)
ClinicalTrials.gov Identifier:	NCT00004364